Meanwhile, the BSE Sensex was down 51.05 points, or 0.28%, to 18,377.56.

On BSE, 23,000 shares were traded in the counter as against an average daily volume of 83,089 shares in the past one quarter.

The stock hit a high of Rs 553 and a low of Rs 546.10 so far during the day. The stock had hit a record high of Rs 565.75 on 6 February 2012. The stock had hit a 52-week low of Rs 404 on 24 February 2011.

The stock had underperformed the market over the past one month until 21 February 2012, gaining 2.79% compared with the Sensex's 10.09% rise. The scrip had also underperformed the market in past one quarter, rising 8.85% as against 15.57% rise in the Sensex.

The large-cap drug maker has an equity capital of Rs 103.56 crore. Face value per share is Re 1.

Lipodox is a generic of Johnson & Johnson's cancer drug Doxil. According to reports, Doxil has been in short supply since about mid-2011.

Caraco, a generic-drug maker based in Detroit, will temporarily import the drug Lipodox from its India-based parent, Sun Pharmaceutical Industries, the FDA said.

Sun Pharmaceuticals Industries' consolidated net profit jumped 91% to Rs 668.30 crore on 37% increase in net sales to Rs 2145.13 crore in Q3 December 2011 over Q3 December 2010.

Established in 1983, listed since 1994 and headquartered in India, Sun Pharma is an international, integrated, speciality pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world. In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, diabetology, gastroenterology, orthopedics and ophthalmology. The company has strong skills in product development, process chemistry, and manufacturing of complex API, as well as dosage forms.

Powered by Capital Market - Live News